Sonnet BioTherapeutics I... (SONN)
NASDAQ: SONN
· Real-Time Price · USD
5.01
-0.04 (-0.79%)
At close: Oct 08, 2025, 10:14 AM
-0.79% (1D)
| Bid | 4.9 |
| Market Cap | 33.57M |
| Revenue (ttm) | 1M |
| Net Income (ttm) | -13.56M |
| EPS (ttm) | -6.82 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -0.06 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 5.05 |
| Volume | 128,026 |
| Avg. Volume (20D) | 1,821,040 |
| Open | 5.05 |
| Previous Close | 5.05 |
| Day's Range | 4.83 - 5.19 |
| 52-Week Range | 1.08 - 19.30 |
| Beta | 1.34 |
| Ex-Dividend Date | n/a |
About SONN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SONN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SONN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+86.46%
Sonnet BioTherapeutics shares are trading higher a...
Unlock content with
Pro Subscription
10 months ago
-5.71%
Sonnet BioTherapeutics shares are trading higher after the company announced the highest dose of its Phase 1 SB101 trial results for SON-1010 have been formally evaluated by the safety review committee, with the maximum tolerated dose set at 1200ng/kg.
